GlassScriptPhysician profile
Sharon J Barthelmes
NPI 1043449705
$8,869.23
in general payments reported to CMS, 2019-2025
41 companies · $1,949 in 2025
The $1,949 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,866 · 2022: $1,545 · 2023: $1,665 · 2024: $1,844 · 2025: $1,949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,458.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,967.79 | 2021-2025 | |
| Lilly USA, LLC | $1,002.72 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $648.17 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $551.85 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $493.59 | 2021-2025 | |
| Novo Nordisk INC | $469.58 | 2021-2025 | Rybelsus, Ozempic, Tresiba |
| Otsuka America Pharmaceutical, INC. | $425.58 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $375.51 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $348.39 | 2021-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $312.17 | 2021-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $230.59 | 2021-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Amgen INC. | $221.58 | 2021-2024 | Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $212.99 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.82 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Dexcom, INC. | $180.41 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Barthelmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.